MD20140037A2 - Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu - Google Patents

Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu Download PDF

Info

Publication number
MD20140037A2
MD20140037A2 MDA20140037A MD20140037A MD20140037A2 MD 20140037 A2 MD20140037 A2 MD 20140037A2 MD A20140037 A MDA20140037 A MD A20140037A MD 20140037 A MD20140037 A MD 20140037A MD 20140037 A2 MD20140037 A2 MD 20140037A2
Authority
MD
Moldova
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
MDA20140037A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Inventor
Шаранджит Каур Багал
Марк Ян Кемп
Дункан Чарльз Миллер
Йосихиса МУРАТА
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20140037(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of MD20140037A2 publication Critical patent/MD20140037A2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MDA20140037A 2011-10-26 2012-10-15 Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu MD20140037A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (1)

Publication Number Publication Date
MD20140037A2 true MD20140037A2 (ro) 2014-08-31

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140037A MD20140037A2 (ro) 2011-10-26 2012-10-15 Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu

Country Status (28)

Country Link
US (1) US9079878B2 (https=)
EP (1) EP2771335A2 (https=)
JP (1) JP5946538B2 (https=)
KR (1) KR101586966B1 (https=)
CN (1) CN103906746B (https=)
AP (1) AP2014007579A0 (https=)
AU (1) AU2012328034B2 (https=)
BR (1) BR112014009102A2 (https=)
CA (1) CA2850925C (https=)
CL (1) CL2014000956A1 (https=)
CO (1) CO6940427A2 (https=)
CR (1) CR20140185A (https=)
CU (1) CU20140046A7 (https=)
DO (1) DOP2014000085A (https=)
EA (1) EA023375B1 (https=)
EC (1) ECSP14013324A (https=)
GT (1) GT201400079A (https=)
IL (1) IL232267A (https=)
MD (1) MD20140037A2 (https=)
MX (1) MX337469B (https=)
NI (1) NI201400031A (https=)
PE (1) PE20141682A1 (https=)
PH (1) PH12014500919A1 (https=)
SG (1) SG11201401032YA (https=)
TN (1) TN2014000147A1 (https=)
UA (1) UA109220C2 (https=)
WO (1) WO2013061205A2 (https=)
ZA (1) ZA201402281B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003064A (es) * 2011-09-14 2014-05-07 Dow Agrosciences Llc Metodos y sistemas para formar acidos boronicos y sus intermedios.
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
US10612042B2 (en) 2014-10-24 2020-04-07 Avectas Limited Delivery across cell plasma membranes
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
CA3009715A1 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
JP7305534B2 (ja) * 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
JP7288051B2 (ja) 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としての2-アミノ-N-ヘテロアリール-ニコチンアミド類
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
HRP20260068T1 (hr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256248A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
ES2346665T3 (es) * 2004-05-07 2010-10-19 Warner-Lambert Company Llc Derivados de fenol y tiofenol 3- o 4-monosustituidos utiles como ligandos de h3.
AR051829A1 (es) * 2004-10-27 2007-02-14 Schering Corp Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia
EP1963280B1 (en) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
EP1995241B1 (en) 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
WO2008135830A1 (en) 2007-05-03 2008-11-13 Pfizer Limited N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
PE20141682A1 (es) 2014-11-14
EP2771335A2 (en) 2014-09-03
DOP2014000085A (es) 2014-08-31
AU2012328034B2 (en) 2015-04-23
JP5946538B2 (ja) 2016-07-06
US9079878B2 (en) 2015-07-14
PH12014500919A1 (en) 2014-06-09
MX2014004738A (es) 2014-08-01
WO2013061205A2 (en) 2013-05-02
CN103906746A (zh) 2014-07-02
IL232267A (en) 2016-10-31
CO6940427A2 (es) 2014-05-09
IL232267A0 (en) 2014-06-30
AP2014007579A0 (en) 2014-04-30
NI201400031A (es) 2014-10-01
CU20140046A7 (es) 2014-10-02
SG11201401032YA (en) 2014-07-30
EA023375B1 (ru) 2016-05-31
NZ623090A (en) 2015-10-30
KR20140069234A (ko) 2014-06-09
BR112014009102A2 (pt) 2017-04-18
CA2850925A1 (en) 2013-05-02
UA109220C2 (uk) 2015-07-27
US20140296313A1 (en) 2014-10-02
KR101586966B1 (ko) 2016-01-19
ZA201402281B (en) 2015-11-25
CR20140185A (es) 2014-06-03
ECSP14013324A (es) 2014-05-31
HK1198650A1 (en) 2015-05-22
CL2014000956A1 (es) 2014-07-18
WO2013061205A8 (en) 2014-03-27
WO2013061205A3 (en) 2013-06-27
MX337469B (es) 2016-03-02
JP2014530900A (ja) 2014-11-20
EA201490864A1 (ru) 2014-08-29
CN103906746B (zh) 2015-12-09
CA2850925C (en) 2017-01-10
GT201400079A (es) 2015-06-02
AU2012328034A1 (en) 2014-05-15
TN2014000147A1 (fr) 2015-09-30

Similar Documents

Publication Publication Date Title
MD20140037A2 (ro) Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2009011816A (es) Derivados de piridina.
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
WO2012007868A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
NZ725008A (en) Compounds for treating spinal muscular atrophy
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
MY148948A (en) Catecholamine derivatives and prodrugs thereof
IN2014CN04530A (https=)
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12015502632A1 (en) Cxcr7 receptor modulators
IN2013DN02555A (https=)

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)